Clinical Trial Update: Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fludarabine and cyclophosphamide with or without oblimersen in relapsed or refractory chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Oblimersen (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Leukemia | Phase 3 | Status: COMPLETED